WSTAM
MRNA icon

Wilbanks Smith & Thomas Asset Management’s Moderna MRNA Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$260K Hold
2,438
– – 0.01% 476
2023
Q4 		$242K Hold
2,438
– – 0.01% 474
2023
Q3 		$252K Sell
2,438
-1,212
-33% -$135K 0.01% 436
2023
Q2 		$443K Buy
3,650
+500
+16% +$66.7K 0.01% 340
2023
Q1 		$484K Hold
3,150
– – 0.02% 308
2022
Q4 		$566K Hold
3,150
– – 0.02% 289
2022
Q3 		$372K Sell
3,150
-400
-11% -$60.7K 0.02% 327
2022
Q2 		$507K Buy
3,550
+400
+13% +$57.2K 0.02% 294
2022
Q1 		$462K Sell
3,150
-127
-4% -$21.4K 0.02% 319
2021
Q4 		$832K Buy
3,277
+1,089
+50% +$318K 0.03% 260
2021
Q3 		$842K Sell
2,188
-950
-30% -$350K 0.03% 239
2021
Q2 		$737K Hold
3,138
– – 0.03% 260
2021
Q1 		$411K Sell
3,138
-150
-5% -$21.7K 0.02% 318
2020
Q4 		$343K Buy
3,288
+4
+0.1% +$405 0.02% 313
2020
Q3 		$232K Hold
3,284
– – 0.01% 353
2020
Q2 		$211K Buy
+3,284
New +$180K 0.01% 367

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's MRNA Position: Q1 2024 in Review

Wilbanks Smith & Thomas Asset Management held its Moderna (MRNA) position steady in Q1 2024 at 2,438 shares worth $260K. The position accounts for 0.01% of the portfolio, ranked #476.

Wilbanks Smith & Thomas Asset Management first reported a position in MRNA in Q2 2020 and has held it in 16 quarters since. The position peaked at $842K in Q3 2021. 903 funds tracked by Wall St. Rank hold MRNA as of Q1 2024.

  • Wilbanks Smith & Thomas Asset Management held 2,438 shares of Moderna worth $260K as of Q1 2024.
  • Wilbanks Smith & Thomas Asset Management left its Moderna share count unchanged in Q1 2024.
  • Moderna made up 0.01% of Wilbanks Smith & Thomas Asset Management's portfolio in Q1 2024, its #476 holding.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Moderna in Q2 2020 and has held it in 16 quarters since.
  • Wilbanks Smith & Thomas Asset Management's Moderna position peaked at $842K in Q3 2021.
  • 903 funds tracked by Wall St. Rank held Moderna as of Q1 2024.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q1 2024, filed 7 May 2024.